Results from papers released Sunday at the 2008 RSNA suggest that a less rigid approach to treatment, coupled with knowledgeable practitioners and judicious patient selection can improve the commercial prospects of outpatient MRI-guided focused ultrasound ablation of uterine fibroids. There are caveats, though.
Results from papers released Sunday at the 2008 RSNA suggest that a less rigid approach to treatment, coupled with knowledgeable practitioners and judicious patient selection can improve the commercial prospects of outpatient MRI-guided focused ultrasound ablation of uterine fibroids. There are caveats, though.
Dr. Suzanne D. LeBlang, medical director of the University Image Guided Therapy Center in Boca Raton, FL, opened her marathon delivery by releasing results of a study on 80 patients who underwent MRgFUS fibroid ablation at her private outpatient clinic.
According to LeBlang, higher post-treatment nonperfused volumes correlate with increased leimyoma shrinkage, which results in improved patient symptoms. Practitioners should strive for treatment NPVs of at least 50% in order to attain better clinical outcomes, she said. This can be achieved by relaxing the treatment guidelines used by most clinical trials and engaging experienced MR operators.
Results from another study presented by LeBlang showed that patients with pelvic-abdominal wall fat deposits of 2.5 cm or larger are at higher risk of failing treatment. This also includes the chances of suffering muscle necrosis from MRgFUS burn. The researcher speculated that fibroids adhering to the muscle wall may transmit heat at higher temperatures when this is surrounded by heavy fat. Careful selection of patients is a must to avoid complications, she said.
MRgFUS use has expanded beyond fibroid ablation nowadays. It's also being used to treat prostate, breast, and bone cancers. Though reimbursement is still not available, the procedure is becoming increasingly popular among nonradiologists. Turf issues are on the horizon, LeBlang said.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.